MENU
+Compare
NERV
Stock ticker: NASDAQ
AS OF
Apr 4 closing price
Price
$1.37
Change
-$0.17 (-11.04%)
Capitalization
9.58M

NERV Minerva Neurosciences Forecast, Technical & Fundamental Analysis

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NERV with price predictions
Apr 04, 2025

NERV's RSI Indicator slumps into oversold zone

The RSI Oscillator for NERV moved into overbought territory on April 04, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NERV advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

NERV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NERV as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NERV turned negative on April 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NERV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NERV entered a downward trend on March 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (13.044). P/E Ratio (7.211) is within average values for comparable stocks, (63.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.822). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (249.684).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NERV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NERV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NERV is expected to report earnings to rise 91.07% to -107 cents per share on May 13

Minerva Neurosciences NERV Stock Earnings Reports
Q1'25
Est.
$-1.07
Q4'24
Missed
by $1.53
Q3'24
Beat
by $3.98
Q2'24
Missed
by $0.12
Q1'24
Missed
by $0.12
The last earnings report on February 25 showed earnings per share of -56 cents, missing the estimate of 97 cents. With 52.08K shares outstanding, the current market capitalization sits at 9.58M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1500 District Avenue
Phone
+1 617 600-7373
Employees
9
Web
https://www.minervaneurosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMRN1.78-0.02
-1.11%
Immuron Limited
WSO478.04-14.48
-2.94%
Watsco
BELFB60.82-3.81
-5.90%
Bel Fuse
ACIU1.66-0.11
-6.21%
AC Immune SA
RARE32.43-2.70
-7.69%
Ultragenyx Pharmaceutical

NERV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with CVAC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-11.04%
CVAC - NERV
38%
Loosely correlated
-8.80%
DNLI - NERV
34%
Loosely correlated
-7.90%
AKRO - NERV
33%
Poorly correlated
-8.15%
ANAB - NERV
30%
Poorly correlated
-4.04%
IMTX - NERV
30%
Poorly correlated
-8.85%
More